JAAN (LIFE) Biotherapeutics

A new class of therapies to treat cardiovascular diseases

Jaan Biotherapeutics, LLC is a private company that is developing novel therapies to activate the cardiac regeneration process in diseased hearts using proprietary technology. The technology manipulates microRNAs to activate an endogenous cardiac muscle regeneration process which has been shut down in the adult human heart during evolution.

Our current focus is Ischemic Heart Disease (IHD), but the therapy can be applied to many cardiac diseases where cardiac muscle regeneration is required, such as cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). We are also developing a therapeutic for hypertrophic cardiomyopathy (HCM).

OBJECTIVE

Jaan Biotherapeutics LLC is currently seeking funding to enable development. Learn more…

NEXT PHASE

Our therapeutics are ready for Investigational New Drug Application filling with clinical testing planned for the year 2022